Patients fearful of Anthem's ER policy: ‘They’ll have to force me into an ambulance’

Brittany Cloyd went into the emergency room in July 2017 with a worsening fever and stomach pain, she told Vox. The 27-year-old's family thought it might be appendicitis. Instead, she was diagnosed with ovarian cysts, a condition her insurer, Anthem, said wasn’t worth a trip to the ER—so it wouldn’t cover her $12,596 hospital bill.

Cloyd is one of the patients affected by Anthem’s controversial ER policy. In an attempt to steer patients toward less expensive sites of care and prevent overutilization, in several states, it’s warned its members they’ll be on the hook for an ER visit if Anthem determines it to be unnecessary.

Emergency physicians, who have been harshly critical of the policy, say very few ER visits are avoidable. Making matters more complicated, Anthem hasn’t outlined its reasons for denying claims in some states. The denial is also based on the patient’s final diagnosis, not symptoms that prompted them to seek care.

“If you look at insurance claims data, you have diagnoses but you don’t have what the patient came in with,” said Renee Hsia, MD, a professor of health policy studies at the University of California San Francisco and practicing emergency physician. “It’s not fair to expect the patient [to come] in knowing their diagnosis. If they did, they wouldn’t come in and wait for ours.”

As for Cloyd, she has appealed her denial twice, to no avail. Only after Vox interviewed her about the bill did Anthem cover her claim. In the future, however, she said she’ll be very hesitant to seek care at the ER—exactly the scenario emergency doctors say they fear.

“I have numerous health issues, and it’s upsetting and scary to think that I don’t have that option, but it’s just not worth the stress,” she said. “I told my husband, I’ll go to primary care, and they’ll have to force me into an ambulance to go to the emergency room.”

Read more at the link below:

""
John Gregory, Senior Writer

John joined TriMed in 2016, focusing on healthcare policy and regulation. After graduating from Columbia College Chicago, he worked at FM News Chicago and Rivet News Radio, and worked on the state government and politics beat for the Illinois Radio Network. Outside of work, you may find him adding to his never-ending graphic novel collection.

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.